Treatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer Employing Radiation, Immuno-oncology and Resection
The SUPER trial is a prospective Phase II trial. It is designed for patients with stage 2 or 3 non-small cell lung cancer (NSCLC) prior to surgery.

Patients who are enrolled in this trial will receive combination of Non-ablative oligofractionated radiation (NORT) and two cycles of Durvalumab, an immunotherapy drug before their surgery.
Lung Cancer Patients|Non-small Cell Lung Cancer (NSCLC)
DRUG: Durvalumab|RADIATION: Non-ablative oligofractionated radiation (NORT)
To Measure CD8 TILs density & Major Pathological Response (MPR), 1. The proportion of patients achieving MPR after neoadjuvant therapy
2. The proportion of patients doubling the CD8 TILs density after neoadjuvant therapy., 5-6 weeks post treatment
To explore the efficacy and safety of NORT-durvalumab, 1. The proportion of patients achieving pCR after neoadjuvant therapy
2. The proportion of patients with grade 3, 4 or 5 toxicity, 12 weeks post surgery
The SUPER trial is a prospective Phase II trial. It is designed for patients with stage 2 or 3 non-small cell lung cancer (NSCLC) prior to surgery.

Patients who are enrolled in this trial will receive combination of Non-ablative oligofractionated radiation (NORT) and two cycles of Durvalumab, an immunotherapy drug before their surgery.